Interestingly, moderately and poorly differentiated adenocarcinomas harbored KRAS mutations (18% and 17% respectively) more frequently than well-differentiated adenocarcinomas, suggesting potential de novo carcinogenesis as a result of KRAS mutations and additional genomic events. This evidence concerns the gene KRAS and adenocarcinoma.